Biogen hit with class-action lawsuit involving Alzheimer’s drug Aduhelm – Clinical Daily News
The maker of the Alzheimer's drug aducanumab (Aduhelm), is the subject of a class-action lawsuit alleging securities fraud. This latest development adds to the ongoing fallout following the Food and Drug Administration's…